Zenith update
From yesterday's presentation:
So on Zenith, that enrollment is going really well. We’ll give a more in depth update next week in our earnings call but I’m really impressed by the pick up lately in terms of excitement in that study and enrollment. The hard part is you and I’ve talked a bunch, Brian, as it’s not a fixed dosing period. It’s following patients with — for three attacks, to treat three attacks. And on average, it takes about four months for a patient to have three attacks to get treated but in some cases, it’s a lot longer.
And so just making sure that the patients that it’s one thing to get them randomized. It’s another thing to follow them through the three attacks. So we will report out data on that study this year, in particular in the high dose cohort, the first one, 750 milligrams. But I can’t give you a whole lot more detail. We’ll give you some enrollment updates next week.